• Users Online: 113
  • Print this page
  • Email this page
QUALITY IMPROVEMENT PROJECT
Year : 2019  |  Volume : 2  |  Issue : 4  |  Page : 105-108

Analysis of vaccination rates of 23-valent pneumococcal polysaccharide vaccine after quality improvement project in hospitalized patients with diabetes mellitus


1 Department of Pediatrics, Irvine Medical Center, University of California, Orange, California, USA; Children’s Hospital of Orange County, Orange, California, USA
2 Department of Pediatrics, Irvine Medical Center, University of California, Orange, California, USA; Children’s Hospital of Orange County, Orange, California, USA; Division of Endocrinology, Irvine Medical Center, University of California, Orange, California, USA
3 Children’s Hospital of Orange County, Orange, California, USA
4 Department of Pediatrics, Irvine Medical Center, University of California, Orange, California, USA; Children’s Hospital of Orange County, Orange, California, USA; Division of Infectious Disease, Irvine Medical Center, University of California, Orange, California, USA

Correspondence Address:
Amy Seagroves
4650 Sunset Blvd, Los Angeles, CA 90027.
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JQSH.JQSH_12_19

Get Permissions

Introduction: Since 2014, the American Academy of Pediatrics has recommended that patients over two years with diabetes mellitus (DM) receive the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Methods: Retrospective chart review was initiated by a quality improvement (QI) project to determine PPSV23 administration rates for inpatients with DM at Children’s Hospital of Orange County (CHOC). The QI project included education for staff and families regarding need for PPSV23 in patients with DM. Electronic medical record (EMR) order sets for DM were updated with PPSV23 vaccine. Data were collected from EMR to identify differences in subjects who were vaccinated with PPSV23 and unvaccinated from April 2015 to April 2016. Results: Before April 2015, PPSV23 was not being given to inpatients with DM. There were 199 individual subjects admitted to CHOC with DM from April 2015 to April 2016. Of those, 78 subjects (39.1%) received vaccine. Data were categorized to identify if vaccine was ordered (n = 152) or not (n = 47). Univariate logistic regression analysis performed on whether PPSV23 was ordered showed age, location (pediatric intensive care unit [PICU] vs. floor), hemoglobin A1c (HbA1c), primary DM admission, and insulin pump vs. injection usage were significant factors (P < 0.05). Multivariate logistic regression showed that those with higher HbA1c (P = 0.014), new-onset DM (P = 0.009), and those admitted for primary DM-related issues (P = 0.007) were more likely to have PPSV23 ordered. No significant subject factors identified differences in why vaccine was not administered (n = 74) once ordered. Conclusion: PPSV23 rates for pediatric inpatients with DM increased from 0% to 39% during one year following education and EMR modifications.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed539    
    Printed44    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal